pharma news today glp-1 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 GLP-1 Receptor Agonist Market Growth
Description
We ensure every batch of glp-1 meets stringent standards for purity, potency, and safety
Numerous analysts have said the GLP-1s are very likely to disrupt certain areas of the MedTech industry, while others say MedTech can live side-by-side with the weight-loss drugs.1 In fact, the impact of GLP-1s is likely to be more nuanced than the blunt conclusions drawn by market watchers, with some companies and segments affected more than others
A study of adults with diabetes suggests patients with obstructive sleep apnea derive a 20% greater mortality reduction from GLP-1 therapy than those without the sleep disorder.
They're looking for real food that happens to work for them
GI, muscle, and bone side effects are some known risks that must be weighed when starting incretin therapy
